Sarah joined Sofinnova as an Associate in 2017. In 2020, she was promoted to Partner. She focuses on biopharmaceutical investments. Sarah currently serves as a Board Member for Inozyme and a Board Observer for Aeovian, Akouos, Antiva, Neurana, and NorthSea. Sarah additionally played a central role in Sofinnova’s investments in Apellis (APLS), Pionyr, and YmAbs (YMAB). She previously served as a Board Member for Promedior prior to its acquisition by Roche for up to $1.4B and Board Observer for NextCure (NXTC) and YmAbs (YMAB).
Prior to joining Sofinnova, Sarah was a postdoctoral fellow in neuroscience at Stanford University in the laboratories of Drs. Robert Malenka and Karl Deisseroth. As a graduate student at Yale, Sarah worked with Dr. Stephen Strittmatter, her thesis advisor and co-founder of Axerion Therapeutics, to identify novel targets and develop therapeutics for CNS injury and psychiatric disorders. Sarah was also a Venture Fellow for Canaan Partners. Prior to Yale, Sarah worked as a research assistant for The Rockefeller University. Before her time at Rockefeller, Sarah was a Clinical Research Coordinator at Massachusetts General Hospital in the Bipolar Clinic and Research Program.
Sarah received her Ph.D. in Neuroscience from Yale University, where she was a National Science Foundation Graduate Research Fellow. Sarah also holds a B.A. in Biological Psychology from Franklin & Marshall College. Sarah is also an alumna of Stanford’s Graduate School of Business Ignite Entrepreneurship and Innovation Program. Sarah is on the board of Stanford’s Neuroscience Translate Oversight Committee.